Crucell
J&J announces ‘major commitment’ to Ebola effort
October 22, 2014Sales and Marketing Crucell, Ebola, J&J, JJ, Vaccine, bavarian, johnson, niaid
Johnson & Johnson will invest $200 million to accelerate and significantly expand the production of its Ebola vaccine programme. The …
J&J to acquire Crucell for $2.3 billion
September 17, 2010Sales and Marketing Crucell, Johnson & Johnson
Johnson & Johnson is set to buy out Crucell for around $2.3 billion (1.75 bn euros) expanding its presence in …
Crucell malaria vaccine starts trials in Africa
May 11, 2010Research and Development Crucell, malaria
Dutch biopharma firm Crucell has started a phase I trial of its AdVac-based malaria vaccine in Burkina Faso, West Africa. …
GSK and Crucell to develop malaria vaccine
April 7, 2010Sales and Marketing Crucell, GSK, malaria
GlaxoSmithKline Biologicals and Dutch vaccines company Crucell are to develop a ‘second generation’ malaria vaccine candidate. Malaria causes 900,000 deaths …
J&J buys stake in vaccines firm Crucell
September 29, 2009Sales and Marketing Crucell, JJ, vaccines
Johnson & Johnson has acquired an 18% stake in Netherlands-based vaccines firm Crucell, and the two companies will work together …
Crucell linked with new takeover suitors
January 29, 2009Sales and Marketing Crucell, MA
Dutch vaccines firm Crucell could be snapped up by other pharmaceutical companies after Wyeth pulled out of negotiations to buy …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
